May 8, 2012

IPOPI releases statement on access to IG Therapies

This new IPOPI statement is intended to provide a summary of IPOPI’s position with regards to the importance of ensuring access for patients living with a primary immunodeficiency (PID) to the best suited immunoglobulin (IG) replacement therapy, as selected and prescribed by their physician.
IPOPI is concerned by recent developments in several countries that may restrict access to the best suited IG therapy for individual patients. To access the statement click here

World PI Week
IPOPI would be grateful for any support to the important work for primary immunodeficiencies.

Read all

Executive Director: Johan Prevot
Tel/Fax: +351 21 407 5720
UK office
Firside Main Road Downderry
Cornwall PL11 3LE
United Kingdom

Tel: +44 1503 250 668
Fax: +44 1503 250 961
IPOPI is a charity registered in the UK.
Registration No. 1058005